PMID- 34408421
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 17
DP  - 2021
TI  - Association Between NR4A2 Gene Polymorphism and Depressive Symptoms and 
      Antidepressant Effect.
PG  - 2613-2623
LID - 10.2147/NDT.S319548 [doi]
AB  - OBJECTIVE: Although the pathogenesis of major depressive disorder (MDD) is still 
      unclear, studies have shown that the dopaminergic system of depressed patients is 
      defective, and that NR4A2 is an important transcription factor affecting the 
      development and maintenance of dopaminergic neurons. As such, NR4A2 levels 
      affected by NR4A2 single nucleotide polymorphisms (SNPs) may be associated with 
      MDD. This study examined whether NR4A2 SNPs are associated with depressive 
      symptoms and antidepressant efficacy. METHODS: A total of 441 patients with 
      first-episode depression were enrolled in this study. We analysed three SNPs of 
      NR4A2, using the 17-item Hamilton Depression Rating Scale (HAM-D) and its four 
      factors to obtain scores at baseline and at the end of 6 weeks. UNPHASED software 
      was employed for quantitative character analysis, and SPSS software was adopted 
      for antidepressant efficacy analysis. RESULTS: Patients with rs12803-A exhibited 
      higher scores of retardation symptoms. Patients with the rs834834-C allele and 
      rs834834-CC genotype had higher retardation symptom scores. Patients with 
      rs3769340 exhibited greater antidepressant efficacy. CONCLUSION: NR4A2 gene 
      polymorphisms are associated with retardation symptoms, somatic symptoms 
      (gastro-intestinal), anxiety-based somatic symptoms, insight, and weight loss in 
      patients with MDD. Additionally, rs3769340 may be a predictor of antidepressant 
      efficacy in patients with major depressive disorder.
CI  - (c) 2021 Song et al.
FAU - Song, Xiaotong
AU  - Song X
AD  - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, 
      People's Republic of China.
AD  - Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental 
      Disorder, First Hospital of Shanxi Medical University, Taiyuan, People's Republic 
      of China.
FAU - Sun, Ning
AU  - Sun N
AD  - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, 
      People's Republic of China.
AD  - Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental 
      Disorder, First Hospital of Shanxi Medical University, Taiyuan, People's Republic 
      of China.
AD  - Department of Mental Health, Shanxi Medical University, Taiyuan, People's 
      Republic of China.
FAU - Zhang, Aixia
AU  - Zhang A
AD  - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, 
      People's Republic of China.
AD  - Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental 
      Disorder, First Hospital of Shanxi Medical University, Taiyuan, People's Republic 
      of China.
AD  - Department of Mental Health, Shanxi Medical University, Taiyuan, People's 
      Republic of China.
FAU - Lei, Lei
AU  - Lei L
AD  - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, 
      People's Republic of China.
FAU - Li, Xinrong
AU  - Li X
AD  - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, 
      People's Republic of China.
FAU - Liu, Zhifen
AU  - Liu Z
AD  - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, 
      People's Republic of China.
AD  - Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental 
      Disorder, First Hospital of Shanxi Medical University, Taiyuan, People's Republic 
      of China.
AD  - Department of Mental Health, Shanxi Medical University, Taiyuan, People's 
      Republic of China.
FAU - Wang, Yanfang
AU  - Wang Y
AD  - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, 
      People's Republic of China.
FAU - Yang, Chunxia
AU  - Yang C
AD  - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, 
      People's Republic of China.
AD  - Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental 
      Disorder, First Hospital of Shanxi Medical University, Taiyuan, People's Republic 
      of China.
AD  - Department of Mental Health, Shanxi Medical University, Taiyuan, People's 
      Republic of China.
FAU - Zhang, Kerang
AU  - Zhang K
AD  - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210810
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC8364372
OTO - NOTNLM
OT  - NR4A2
OT  - antidepressant treatment
OT  - major depressive disorder
OT  - single nucleotide polymorphism
COIS- The authors report no conflicts of interest for this work.
EDAT- 2021/08/20 06:00
MHDA- 2021/08/20 06:01
PMCR- 2021/08/10
CRDT- 2021/08/19 06:36
PHST- 2021/05/18 00:00 [received]
PHST- 2021/07/23 00:00 [accepted]
PHST- 2021/08/19 06:36 [entrez]
PHST- 2021/08/20 06:00 [pubmed]
PHST- 2021/08/20 06:01 [medline]
PHST- 2021/08/10 00:00 [pmc-release]
AID - 319548 [pii]
AID - 10.2147/NDT.S319548 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2021 Aug 10;17:2613-2623. doi: 10.2147/NDT.S319548. 
      eCollection 2021.